This company listing is no longer active
Satsuma Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Satsuma Pharmaceuticals's earnings have been declining at an average annual rate of -33.2%, while the Pharmaceuticals industry saw earnings growing at 19.4% annually.
Información clave
-33.2%
Tasa de crecimiento de los beneficios
46.0%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 7.3% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera | -172.2% |
| Margen neto | n/a |
| Última actualización de beneficios | 31 Mar 2023 |
Actualizaciones de resultados anteriores recientes
No hay actualizaciones
Recent updates
Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Satsuma Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -65 | 14 | 40 |
| 31 Dec 22 | 0 | -70 | 15 | 44 |
| 30 Sep 22 | 0 | -62 | 16 | 47 |
| 30 Jun 22 | 0 | -61 | 15 | 46 |
| 31 Mar 22 | 0 | -56 | 14 | 42 |
| 31 Dec 21 | 0 | -51 | 14 | 38 |
| 30 Sep 21 | 0 | -48 | 13 | 35 |
| 30 Jun 21 | 0 | -47 | 14 | 33 |
| 31 Mar 21 | 0 | -46 | 13 | 34 |
| 31 Dec 20 | 0 | -48 | 12 | 36 |
| 30 Sep 20 | 0 | -46 | 11 | 36 |
| 30 Jun 20 | 0 | -42 | 8 | 35 |
| 31 Mar 20 | 0 | -37 | 7 | 32 |
| 31 Dec 19 | 0 | -28 | 5 | 24 |
| 30 Sep 19 | 0 | -20 | 3 | 17 |
| 30 Jun 19 | 0 | -13 | 2 | 11 |
| 31 Mar 19 | 0 | -8 | 1 | 7 |
| 31 Dec 18 | 0 | -7 | 1 | 6 |
Ingresos de calidad: 1LV is currently unprofitable.
Margen de beneficios creciente: 1LV is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 1LV is unprofitable, and losses have increased over the past 5 years at a rate of 33.2% per year.
Acelerando crecimiento: Unable to compare 1LV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: 1LV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.4%).
Rentabilidad financiera
Alta ROE: 1LV has a negative Return on Equity (-172.21%), as it is currently unprofitable.